SE0593656T3 - - Google Patents

Info

Publication number
SE0593656T3
SE0593656T3 SE92915686T SE92915686T SE0593656T3 SE 0593656 T3 SE0593656 T3 SE 0593656T3 SE 92915686 T SE92915686 T SE 92915686T SE 92915686 T SE92915686 T SE 92915686T SE 0593656 T3 SE0593656 T3 SE 0593656T3
Authority
SE
Sweden
Application number
SE92915686T
Other languages
Swedish (sv)
Other versions
SE0593656E5 (sv
SE0593656T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0593656(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of SE0593656T3 publication Critical patent/SE0593656T3/sv
Publication of SE0593656E5 publication Critical patent/SE0593656E5/sv
Publication of SE0593656T6 publication Critical patent/SE0593656T6/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Paints Or Removers (AREA)
  • Saccharide Compounds (AREA)
SE92915686T 1991-07-08 1992-07-03 Nya kompositioner baserade på taxanderivat SE0593656E5 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Publications (3)

Publication Number Publication Date
SE0593656T3 true SE0593656T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-02-03
SE0593656E5 SE0593656E5 (sv) 2010-11-30
SE0593656T6 SE0593656T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-11-30

Family

ID=9414814

Family Applications (1)

Application Number Title Priority Date Filing Date
SE92915686T SE0593656E5 (sv) 1991-07-08 1992-07-03 Nya kompositioner baserade på taxanderivat

Country Status (28)

Country Link
US (1) US5403858A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP0593656B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPH06507914A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0136722B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE147992T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2102777C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ280965B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69217056D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK0593601T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2096091T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI111808B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2678833B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP19991517B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (2) GR3022355T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1006207A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU217839B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE80548B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX9203959A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO307206B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL169372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2134123C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE0593656E5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG80541A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK279946B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW577752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO1993000928A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU48913B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA924999B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
DK0706376T4 (da) * 1993-07-19 2007-12-10 Angiotech Pharm Inc Antiangiogene præparater og fremgangsmåder til anvendelse
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
AU2826495A (en) * 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
CA2195623A1 (en) * 1994-07-22 1996-02-08 Rajeev D. Gokhale Self-emulsifying drug delivery system
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2240595A1 (en) * 1995-12-21 1997-07-03 Bijan Almassian Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CN1177934C (zh) 1997-04-28 2004-12-01 阿文蒂斯药物股份有限公司 腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
DE19983660T1 (de) 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1498084B1 (en) 2000-10-16 2014-06-18 Innovational Holdings, LLC Expandable medical device for delivery of beneficial agent
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
WO2003099346A2 (en) * 2002-05-24 2003-12-04 Angiotech International Ag Compositions and methods for coating medical implants
AU2003276920A1 (en) * 2002-09-20 2004-04-08 Innovational Holdings, Llc Expandable medical device with openings for delivery of multiple beneficial agents
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
EA200501252A1 (ru) 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
CA2536242A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
SG162798A1 (en) 2005-06-17 2010-07-29 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
AP3552A (en) 2010-05-03 2016-01-18 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2753355B1 (en) 2011-09-08 2018-10-24 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
CN108158991A (zh) 2012-07-19 2018-06-15 富士胶片株式会社 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
TW202515912A (zh) 2014-03-21 2025-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
ES2861499T3 (es) 2016-06-08 2021-10-06 Abbvie Inc Anticuerpos anti-B7-H3 y conjugados anticuerpo-fármaco
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
US11957758B2 (en) 2017-09-07 2024-04-16 Shenzhen Salubris Pharmaceuticals Co. Ltd. Pharmaceutical composition of docetaxel conjugate and preparation method
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
EP3823608A4 (en) 2018-09-05 2022-05-11 Emcure Pharmaceuticals Limited STABLE READY-TO-USE PHARMACEUTICAL CARMUSTI COMPOSITION
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
EP0522936A1 (fr) 1993-01-13
KR0136722B1 (ko) 1998-04-25
WO1993000928A1 (fr) 1993-01-21
ATE147992T1 (de) 1997-02-15
US5403858A (en) 1995-04-04
AU2278792A (en) 1993-02-11
RU2134123C1 (ru) 1999-08-10
FR2678833B1 (fr) 1995-04-07
EP0522937A1 (fr) 1993-01-13
SK279946B6 (sk) 1999-06-11
FI940074A0 (fi) 1994-01-07
DE69223624T2 (de) 1998-04-23
DE69217056D1 (de) 1997-03-06
EP0593601A1 (fr) 1994-04-27
YU48913B (sh) 2002-11-15
IE922212A1 (en) 1993-01-13
MX9203960A (es) 1993-01-01
NO934609D0 (no) 1993-12-14
GEP19991517B (en) 1999-03-05
JPH06507913A (ja) 1994-09-08
HU217839B (hu) 2000-04-28
FI940074L (fi) 1994-01-07
GR3022355T3 (en) 1997-04-30
FI940073L (fi) 1994-01-07
NO934610L (no) 1993-12-14
CA2102778A1 (fr) 1993-01-09
CA2102778C (fr) 2004-04-20
CA2102777A1 (fr) 1993-01-09
DE69223624D1 (de) 1998-01-29
FR2678833A1 (fr) 1993-01-15
EP0593601B1 (fr) 1997-12-17
HU9400052D0 (en) 1994-05-30
AU666859B2 (en) 1996-02-29
DE69217056T2 (de) 1997-06-05
DE69217056T4 (de) 2009-08-20
SK1594A3 (en) 1994-10-05
DK0593601T3 (da) 1998-02-09
ATE161193T1 (de) 1998-01-15
CZ280965B6 (cs) 1996-05-15
WO1993000929A1 (fr) 1993-01-21
FI111807B (fi) 2003-09-30
NO934609L (no) 1993-12-14
ES2096091T3 (es) 1997-03-01
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21
ES2110003T3 (es) 1998-02-01
HUT65960A (en) 1994-08-29
JP2595458B2 (ja) 1997-04-02
IE922213A1 (en) 1993-01-13
PL169372B1 (en) 1996-07-31
GR3025714T3 (en) 1998-03-31
HK1006207A1 (en) 1999-02-12
FI111808B (fi) 2003-09-30
MX9203959A (es) 1993-01-01
JPH06507914A (ja) 1994-09-08
CA2102777C (fr) 2004-09-07
NO307205B1 (no) 2000-02-28
ZA924999B (en) 1993-04-28
IE80548B1 (en) 1998-09-09
NO934610D0 (no) 1993-12-14
EP0593656A1 (fr) 1994-04-27
IE80461B1 (en) 1998-07-29
ES2096091T7 (es) 2010-03-31
FI940073A0 (fi) 1994-01-07
TW577752B (en) 2004-03-01
EP0593656B3 (fr) 2009-10-07
CZ3294A3 (en) 1995-02-15
DK0593656T5 (da) 2010-01-11
SE0593656E5 (sv) 2010-11-30
SG80541A1 (en) 2001-05-22
DK0593656T3 (da) 1997-02-10
SE0593656T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-11-30
YU67692A (sh) 1995-12-04
DE69217056T3 (de) 2010-04-22
EP0593656B1 (fr) 1997-01-22

Similar Documents

Publication Publication Date Title
FR2672893B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0497252A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE4290581T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0504932A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE4291719T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0498143T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE4291050T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2671746B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0549891T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0549782T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0545490T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE4292011T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK132791D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH0490138U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7834891A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91549U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91536U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN172036B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91556U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91526U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN175280B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK197691D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91539U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91555U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91550U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)